Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Anika Therapeutics (ANIK) Other Gross PP&E Adjustments (2016 - 2026)

Anika Therapeutics has reported Other Gross PP&E Adjustments over the past 17 years, most recently at $65.1 million for Q1 2026.

  • Quarterly Other Gross PP&E Adjustments rose 9.38% to $65.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $65.1 million through Mar 2026, up 9.38% year-over-year, with the annual reading at $64.0 million for FY2025, 12.09% up from the prior year.
  • Other Gross PP&E Adjustments was $65.1 million for Q1 2026 at Anika Therapeutics, up from $64.0 million in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at $65.1 million in Q1 2026 and troughed at -$34.8 million in Q2 2022.
  • The 5-year median for Other Gross PP&E Adjustments is -$26.0 million (2025), against an average of $6.6 million.
  • Year-over-year, Other Gross PP&E Adjustments plummeted 59.13% in 2022 and then skyrocketed 308.31% in 2025.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at $60.6 million in 2022, then fell by 14.87% to $51.6 million in 2023, then grew by 10.67% to $57.1 million in 2024, then grew by 12.09% to $64.0 million in 2025, then increased by 1.75% to $65.1 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Other Gross PP&E Adjustments are $65.1 million (Q1 2026), $64.0 million (Q4 2025), and -$26.0 million (Q3 2025).